

From lives once on
hold to futures within
reach.

eGenesis

18M

People globally suffer from organ failure

THE VAST MAJORITY WILL DIE WAITING FOR A TRANSPLANT



It's like a gift from God. I'm free.
I can feel good and I can be human again. ”

TIM ANDREWS





+52

DAYS

Dialysis Independence



+271

DAYS

Dialysis Independence



+214

DAYS & COUNTING

Transplanted June 14, 2025

Dialysis Independence











+53













DAYS & COUNTING

Transplanted November 22, 2025

Dialysis Independence



33 more people will join this journey



Less than 5% of people with kidney failure receive transplants

22k

kidney transplants performed in 2023

554k

living with kidney failure, receiving chronic dialysis in 2023

INCLUDING THOSE LISTED FOR KIDNEY TRANSPLANT

Kidney failure

800k

Americans suffer from
kidney failure

INCLUDING THOSE LIVING WITH KIDNEY
FAILURE, LISTED FOR TRANSPLANT,
LIVING WITH KIDNEY ALLOGRAFT

Liver failure

330k

Americans hospitalized annually
for acute liver decompensation

INCLUDING THOSE WITH ACUTE LIVER
FAILURE (ALF), ACUTE ON CHRONIC LIVER
FAILURE (ACLF), AND ACUTE ALCOHOLIC
HEPATITIS

Heart failure

300k

Americans suffer from end-stage
heart failure

REPRESENTING 5% OF THE 6.7M
AMERICANS WITH ALL STAGES OF HEART
FAILURE

\$80B+

Annual U.S. healthcare spend across end-stage organ disease

Uniquely focused on 3 classes of edits addressing both retroviral risk and improving immunologic and molecular compatibility

Genome Modifications


Inactivation	✕	Pathogen Safety	Inactivation of porcine retroviruses
Knock-outs	←	Elimination of Hyperacute Rejection	GGTA1 B4GalNT2 CMAH
Knock-ins	→	HUMAN TRANSGENES	
		Coagulation	PROCR THBD
		Inflammation/ Apoptosis	HMOX1 TNFAIP3
		Innate Immunity	CD47
		Complement	CD46 CD55



Kidney

EGEN-2784


- Clinical Stage IND cleared 2025
- Initiation of Phase 1/2/3 study this year



Liver

EGEN-5784 ELC


- Clinical Stage IND cleared 2025
- Phase 1/2 study initiated



Heart

EGEN-4467

- Preclinical
- Demonstrated record 2+ years survival in baboon



Track record of transformative progress




	2017	2018	2019	2020	2021	2022	2023	2024	2025
Engineering & Bioinformatics		First successful production of donors with retroviral inactivation (Made cover of Science, 2017)		Produced early payloads	Produced first transgenic donor addressing 3 classes of edits		Advanced multiple transgenic donors into development		
Partnerships		Mass General Brigham	ICBiotec	Eledon Pharmaceuticals	KARIUS	Penn UNIVERSITY OF PENNSYLVANIA	ParMedTec	TERUMO	OrganOx
Production			Acquired ICBiotec to establish internal production		Began producing donors in DPF environment		Established GMP cloning and production	Clinical GMP production fully operational	
Nonclinical Development				First NHP recipient achieves 9 months survival (2019). Multiple NHP recipients surpass 2 years survival			Landmark preclinical study (Nature, 2023) showing most extensive xenotransplant dataset with EGEN-2784 demonstrating superior outcomes vs. kidneys with fewer edits		
Clinical Development								World's first pig kidney transplant in living human recipient	3 additional transplants conducted Achieved record 271 days dialysis independence

EGEN-2784

Kidney Failure

Staggering Burden.
Extraordinary Opportunity
to Save + Transform Lives.

- IND clearance to conduct Phase 1/2/3 study in patients over 50 and waitlisted for transplant
- 4 transplants completed to date under Expanded Access
- Record of 271 days dialysis independence



Phase 1/2/3 Registration Study

In patients with End-Stage Kidney Disease

Supported by landmark outcomes in NHP transplant studies and success with patients in the Expanded Access studies

Patient Criteria

- Age 50-70
- On dialysis > 3 months
- No living donor
- <50% chance of transplant in 5 years

Study Outcomes

- Graft function at 6-months
- Cardiovascular safety
- Quality of life
- Pathogen safety

Part 1

SEQUENTIAL ENROLLMENT

- 3 Patients
- 12 weeks between transplants
- Single Site: MGH

Part 2

PARALLEL ENROLLMENT

- 30 Patients
- No sentinel period
- Up to 10 Sites


EGEN-5784 ELC

Liver Failure



Acute Need, Rapid Clinical Endpoint.



- IND clearance to conduct Phase 1/2 study in patients in acute liver failure
- Potential to bridge patients to transplant or support native liver recovery
- Proof of concept established in hepatectomized, decedent patient



Physiological Support for a Patient without a Functioning Liver



Phase 1/2 Study

In patients with Acute-on-Chronic Liver Failure

IND cleared by FDA for Phase 1/2 study in patients with ACLF.
Expect first patient to be enrolled in Q1

Patient Criteria

- Age 18-70
- Ineligible for transplant at enrollment
- Grade 2 or 3 ACLF
- Hepatic encephalopathy Grade 1 to 3

Study Outcomes

- Metabolic and liver function
- ACLF score
- Hepatic encephalopathy
- Adverse Events

Part 1

SEQUENTIAL ENROLLMENT

- 6 Patients
- Up to 2 Sites
- Targeting 72 hours of perfusion


Part 2

PARALLEL ENROLLMENT

- 14 Patients
- Up to 8 Sites
- Targeting 120 hours of perfusion

Enormous value creation over the next 12-18 months

Clinical Development



Advances in xenotransplantation are giving our community hope that new options may soon be available for those who need them most. ”

KEVIN LONGINO
CEO, NATIONAL KIDNEY FOUNDATION



